

In the Claims

Applicant has submitted a new complete claim set showing marked up claims with insertions indicated by underlining and deletions indicated by strikeouts and/or double bracketing.

Please cancel claims 1-36 without prejudice. Please add new claims 37-45, as indicated below.

1-36. (Canceled).

37. (New) An oligonucleotide, comprising: 5'-TGACGTT-3', 5'TGACGTC3' or 5'-AACGTT-3', 8-40 nucleotides in length, and having at least one phosphate backbone modification.

38. (New) The oligonucleotide of claim 37, wherein the oligonucleotide is linked to a nucleic acid delivery complex.

39. (New) The oligonucleotide of claim 38, wherein the oligonucleotide is ionically linked to or encapsulated in the nucleic acid delivery complex.

40. (New) The oligonucleotide of claim 38, wherein the oligonucleotide is covalently linked to the nucleic acid delivery complex.

41. (New) The oligonucleotide of claim 38, wherein the nucleic acid delivery complex is a cationic lipid.

42. (New) The oligonucleotide of claim 38, wherein the nucleic acid delivery complex is a sterol.

43. (New) The oligonucleotide of claim 37, wherein the oligonucleotide comprises 5'-TCAACGTT-3'

44. (New) The oligonucleotide of claim 42, wherein the phosphate backbone modification is a phosphorothioate.

45. (New) A composition comprising the oligonucleotide of claim 37 and a pharmaceutically acceptable carrier.